颠倒的规则
别骂规则，规则只是工具。问题是，谁在拿这把刀？
三件事摆在一起，你很难忍住不骂街。
LV 把中国传统纹样往自己衣服上一贴，摇身一变成了年度爆款，全球收割。中国企业用同样元素做国风产品，LV 反手一个侵权投诉，平台下架、赔偿警告，一条龙。
视觉中国全网爬虫抓你的原创图片，未经授权收进自家版权库，然后再用爬虫抓全网谁用了这些图——包括原创者自己——然后起诉侵权，索赔，按流水线结算。日均打官司十几起，一年几百场，打得比外卖骑手还勤。
《我不是药神》里的现实版本：卖假药的贩子赚得盆满钵满，没人管。患者家属代购印度便宜真药，被判销售假药罪，坐牢。救命的人坐牢，害命的人数钱。
这三件事放在一起，表面看是各骂各的。
但如果你只骂一个骂一个，你就被带偏了。因为它们共享同一个底层逻辑：规则已经变成了一门生意，谁掌握了规则的解释权和执行权，谁就拥有了收割权。
一、LV 的事：文化产业链上的收租
LV 的问题根本不是"挪用了中国文化"。文化从来就是在流动中活着的，佛教从印度来，瓷器从中国走，丝绸从长安到罗马——谁也没拦着。
问题是：谁收钱？
LV 从中国纹样里收割了真金白银的利润，转头就用手里的知识产权大棒打中国企业。它用的是同一套纹样，但它是"灵感"，中国品牌就是"抄袭"。
这不是双标，这是定价权。
LV 的商业模式从来不是在卖包，是在卖"我有资格用这纹样，你没有"的定价话语权。它用百年品牌的势能、全球法务团队的战斗力、西方奢侈品圈的定价权，把公共文化资源私有化了。私有化之后，再反过来收租。
中国品牌在这个链条里的位置是什么？是租客。
你想用祖上传下来的纹样？可以。要么交钱（买授权），要么挨打（被起诉），要么别碰（转设计方向）。而 LV 自己，不需要向任何人交租。因为它站在规则制定者的那一边。
这不是什么"文化挪用"的伤感叙事，这是谁的律师团更狠的游戏。
二、从 LV 到视觉中国：规则生意的高级玩法
LV 玩的还是传统版本——品牌够大、法务够强、规则为我所用。
视觉中国玩的是 2.0 版本：我自己造规则，自己运营规则，自己执行规则。
来，拆一下视觉中国这条"规则供应链"，三个环节：
上游：版权寻矿 爬虫每天扫全网图片，标注"疑似侵权"。不管这图是谁拍的、有没有授权，先收进数据库再说。关键是——它不收自己的图，不收合作方的图，它收的是别人没登记、没打水印、没主动维权的图。挑软柿子捏。
中游：版权包装 把收来的图打上自己的版权标签，上架销售。一张图卖几十到几百。原作者来投诉？"您先证明是您拍的，我们核实后下架。"——举证责任转嫁给创作端。
下游：狩猎与收割 再扫一遍全网，发现谁用了这张图——哪怕是你自己拍的照片发在你自己的网站上——发函、施压、起诉、和解。为什么大多数官司都走和解？因为打官司的成本高于和解费，大多数个人创作者耗不起。
这就是一条标准化的流水线。原料是你的原创，加工是它的标签，销售是它的诉讼，产品是和解费。日均十几场官司不是愤怒，是营收。
戴建峰拍星空拍了三十年，173 张原创被视觉中国盗了，反过来被索赔 8.5 万。他不是第一个，也不会是最后一个。
三、从版权到人命：规则生意的终极版本
前两个故事让你觉得愤怒。第三个故事让你觉得冷。
盗版药被抓——没问题，法律禁止销售未经批准的药品，天经地义。
问题在于：为什么卖假药的人不抓？
《药神》原型陆勇案——他不是卖假药的，他是买了印度仿制药，自己吃着有效，帮病友代购。一分钱没赚，倒贴时间倒贴精力。帮助成千上万个绝症患者吃上了买得起的药。
结果是什么？
以"销售假药罪"被公诉。
那个买药的患者呢？他们去公安局门口请愿，联名写信，说陆勇是救命恩人。
你在法律条文的框架内解释不了这个矛盾。必须跳出条文，看利益的分配链条。
在这条链条上：
- 顶端：拥有专利的原研药公司。它在美国卖几百美元，在中国卖同样价格——但中国的人均收入不是美国水平。这叫全球统一定价，合理合法。
- 中端：药监局。批不批廉价仿制药是复杂的政治经济学问题——廉价药进来，原研药利润受损，外企不高兴。而不引入，"我们不鼓励用海外未获批药物"，也说得过去。
- 底端：患者。吃不起正版，买不起印度版，等死。
陆勇干的事，就是跳过了中端和顶端这两层，直接从底端打通了一条去印度的买药通道。
他动了谁的蛋糕？不是道德问题，是动了利益分配结构。
所以法律这把刀砍下来的方向很明确：不是砍向顶端（动不了），不是砍向中端（自己人），是砍向底端——砍那个帮别人活下去的人。
"销售假药罪"里，有没有"救人"的豁免条款？没有。因为法律的制定不是为了考虑你在饿死和偷面包之间的选择。文字就是文字。
四、过渡层：三件事的精算共通点
现在回头看这三件事，你会发现它们共享一套精算逻辑：
| 项目 | 执行对象 | 被放过对象 | 规则方向 |
|---|---|---|---|
| 知识产权 | 中国企业 | LV | 向下执行 |
| 版权保护 | 原创者/使用者 | 视觉中国 | 向下执行 |
| 药品监管 | 代购者 | 假药贩子/药厂 | 向下执行 |
规则永远向下执行，从不向上追责。
为什么？
因为向下执行成本低、收益高。个体创作者扛不起律师费，所以和解；患者扛不起原研药，所以违法；中国企业扛不起跨国诉讼，所以妥协。
向上追责呢？LV 背后是 LVMH 集团，法务团队规模比大部分中国律所都大。视觉中国的法务经过十年磨合，形成了标准的诉讼流程。药厂背后有专利壁垒、外交筹码、行业协会。
这不是什么阴谋论。这是执行力梯度——法律永远优先砍向最容易砍的人。就像警察永远优先拦看着就像会罚的人，而不是拦豪车。
五、不是规则错了，是规则只能这样
很多人在这种时候会说："规则是好的，是执行出了问题。"
放屁。
如果一个规则从设计之初就没考虑过执行成本的差异，那它就是有偏向的。知识产权制度的设计者没考虑过跨国公司的法律资源优势吗？考虑过。药品监管制度的设计者没考虑过专利药物定价和国民收入的剪刀差吗？考虑过。
它们考虑过。然后做出了选择。
这个选择不是写在条文里的，而是写在"谁有资源推动规则"里的。大资本有立法游说能力，有媒体话语权，有法律解释权。个体没有。
所以规则只会越来越倾向于有资源的一方。不是因为坏人变多了，而是因为规则作为一种社会基础设施，天然倾向于服务最先学会使用它的人。
先学会用的是谁？是律师、法务、公关、咨询师——这些服务资本的专业人士。
最晚学会用的是谁？是你、我、拍星空的摄影师、吃不起药的患者。
六、那你怎么办？
这个问题才是正经要回答的。骂完走人，是假痛快。
你别指望规则某一天突然变公平。公平不是写出来的，是争出来的。
三条路，看你的资源选一条：
1. 抱团 个体打不过视觉中国。但如果一千个摄影师联合起诉、共享律师费、共享证据链呢？版权侵权的单个案值低，但并案后的威慑力完全不同。法务成本是可以摊薄的。
2. 绕道 中国纹样被 LV 收租了，中国企业有没有可能直接找非遗传承人合作，建立"非授权不可用"的正向版权池？把公共文化资产变成有组织的公有池，资本要用就付费入池。法律不保护你，你自己保护自己的资源。
3. 硬杠 陆勇选了这条路。不是每个人都扛得住，但总有人扛。
这三种选择有一个共同点：都不指望规则来救你。
规则是后置的。谁先定义了事实，谁就定义了边界。谁先形成了合力，谁就拥有了议价权。
归根到底一句话：规则从不善良，它只记录力量对比。
你想让规则保护你，你得先证明你有值得保护的力量。
否则，你今天骂的是视觉中国，明天骂的是药监局，后天骂的是资本双标。骂了一圈，发现刀还是落你身上。
不如花点时间，想想怎么让自己变成那个有解释权的人。
——反正规则是不等人的。它永远在等强者。
如果我们的法律不去改变，没有维护到公平和正义。那就放弃这条途径。不要说公平正义不会缺席，只是迟到。迟到的公平正义还叫公平正义吗？迟到了还有意义吗？
Inverted Rules: When Protection Becomes Exploitation
Three stories that look unrelated—but share the same skeleton.
Story one: LV appropriates traditional Chinese patterns, turns them into global bestsellers. When Chinese brands use the same elements, LV sues them for infringement. Same patterns, different rules.
Story two: A stock-photo agency scrapes the web for unmarked images, adds them to its own catalog, then sues the original creators for using their own work. Hundreds of lawsuits a year. It's not anger—it's a business model.
Story three: In the real-life version of Dying to Survive, a cancer patient buys affordable generic drugs from India, shares them with fellow patients. He's charged with selling counterfeit medicine. The real counterfeiters? Untouched.
One thread runs through all three: rules have become a commodity. Whoever controls their interpretation and enforcement controls the revenue stream.
I. LV: Rent Collection on the Culture Chain
The problem isn't "cultural appropriation." Culture has always traveled. The problem is: who collects the check?
LV monetizes public cultural heritage, then uses IP law to block competitors from accessing the same resources. This isn't a double standard—it's pricing power.
The business model isn't selling bags. It's selling the right to say "I can use this, you can't." LV privatized a public good and now charges rent. Chinese brands are tenants in their own cultural house.
Don't dress this up as cultural grievance. Call it what it is: whose legal team is bigger.
II. From Luxury to Litigation: Rules-as-a-Service 2.0
Visual China took the model one step further. Instead of leveraging existing rules, they built their own enforcement machine.
Three-tier supply chain:
Upstream — Scouting: Crawl the web for images without watermarks or formal registration. Store them in your database. Target the defenseless.
Midstream — Packaging: Slap your copyright label on them. List them for sale. When the original creator complains, shift the burden of proof.
Downstream — Harvesting: Scan again. Find anyone using "your" images. Send legal threats. Sue. Settle. Most cases settle because the cost of fighting exceeds the settlement fee.
This is an assembly line. Raw material: someone else's creativity. Processing: your legal claim. Product: settlement revenue. A dozen lawsuits a day isn't righteous anger—it's income.
III. From IP to Life and Death: Rules at Their Coldest
The first two stories make you angry. The third makes you cold.
The real version of Dying to Survive: Lu Yong helped leukemia patients buy affordable Indian generics. He charged nothing. He saved lives.
He was charged with selling counterfeit medicine.
The actual counterfeiters? Never touched.
This contradiction can't be explained within the legal text. You have to look at the interest structure:
- Top: Patent holders. Global pricing, local pain. Legally flawless.
- Middle: Regulators. Approving cheap generics creates diplomatic and economic complications.
- Bottom: Patients. Can't afford the original, can't legally access the alternative.
Lu Yong short-circuited the entire chain. He built a direct pipeline from patient to affordable drug. He disrupted the revenue structure.
The law didn't hit the top (untouchable) or the middle (friendlies). It hit the bottom—the man helping people live.
There's no "good-faith lifesaving" exemption in the counterfeit drug statute. By design.
IV: What They Share
All three cases follow the same vector: rules are enforced downward, never upward.
| Issue | Who gets punished | Who gets a pass | Direction |
|---|---|---|---|
| IP | Chinese brands | LV | Downward |
| Copyright | Original creators | Aggregator | Downward |
| Drug regulation | Patient advocates | Manufacturers | Downward |
Why? Because downward enforcement is cheap. Individuals can't afford to fight. Companies can't afford global litigation. Patients can't afford to wait.
Upward enforcement is expensive. LV has more lawyers than most Chinese firms have employees. Visual China's legal department has a decade of optimized process. Big pharma has patents, lobbying power, and trade leverage.
This isn't a conspiracy. It's enforcement gradient—the law always cuts toward the path of least resistance.
V: The Rules Aren't Broken—They're Working as Designed
"The rules are good, the implementation is flawed."
No.
If a rule was designed without accounting for enforcement cost asymmetry, the asymmetry is the design.
IP law's drafters knew multinationals would have more legal resources. Drug regulations' authors knew the pricing gap was lethal. They considered it. Then they made their choice.
Rules, as social infrastructure, naturally serve those who learn to use them first. That's not malice—it's physics. The heaviest object wins in a collision.
The first to master the rules: lawyers, lobbyists, PR firms—professionals who serve capital.
The last to learn: you, me, photographers who just want to shoot the stars, patients who just want to live.
VI: So What Do You Do?
Don't wait for fairness to descend from above. Fairness isn't written—it's fought for.
Three paths, pick based on your resources:
1. Combine One photographer can't beat Visual China. A thousand with pooled legal funds and shared evidence? Different story. Case value compounds.
2. Bypass LV took Chinese patterns. What if Chinese brands build a certified "public heritage" pool—no unauthorized commercial use, pay to play? Protect your own resources when the law won't.
3. Fight Lu Yong chose this path. Not everyone can afford it. But someone always does.
Common denominator among all three: none of them waits for the rules to save them.
One line to end on: Rules aren't kind. They record the balance of power.
If you want the rules to protect you, prove you're worth protecting. Otherwise you'll cycle from one outrage to the next, and the blade will keep falling on the same necks.
Stop yelling. Start organizing.
The rules aren't waiting. They never do.
If the law refuses to change—if it fails to uphold fairness and justice—then abandon that path. Don't tell me justice is never absent, only delayed. Delayed justice—is that still justice? Does it still mean anything when it finally arrives?
When I wrote about Visual China's business model a while back, someone asked: "So what's your solution?" This article is that answer. If you read it and feel uncomfortable—good. That discomfort is the start of thinking about power, not just outrage.